{"pmid":32373998,"title":"The viral, epidemiologic, clinical characteristics and potential therapy options for COVID-19: a review.","text":["The viral, epidemiologic, clinical characteristics and potential therapy options for COVID-19: a review.","Coronavirus Disease-2019 (COVID-19) caused by SARS-CoV-2 infection has rapidly spread all over the world, in just two months. As of 27 March, globally, 509,164 cases confirmed included 23,335 deaths in approximately 150 countries. Recently, WHO has defined COVID-19 as a global pandemic, and considerable researches have focused on the identification and prevention of SARS-CoV-2. As a result, accumulated publications successively reported their early findings, leading to the constant updating of information, which might make confusion for readers. Therefore, this review summarized the current researches about the genomic evolution, variation of SARS-CoV-2, and demonstrated its viral structure for pathogenesis. Meanwhile, we analyzed the epidemiologic and clinical characteristics of COVID-19, in order to provide recommendations for present clinical treatments and inspirations for potential therapy options.","Eur Rev Med Pharmacol Sci","Li, C","Xu, B-H","32373998"],"abstract":["Coronavirus Disease-2019 (COVID-19) caused by SARS-CoV-2 infection has rapidly spread all over the world, in just two months. As of 27 March, globally, 509,164 cases confirmed included 23,335 deaths in approximately 150 countries. Recently, WHO has defined COVID-19 as a global pandemic, and considerable researches have focused on the identification and prevention of SARS-CoV-2. As a result, accumulated publications successively reported their early findings, leading to the constant updating of information, which might make confusion for readers. Therefore, this review summarized the current researches about the genomic evolution, variation of SARS-CoV-2, and demonstrated its viral structure for pathogenesis. Meanwhile, we analyzed the epidemiologic and clinical characteristics of COVID-19, in order to provide recommendations for present clinical treatments and inspirations for potential therapy options."],"journal":"Eur Rev Med Pharmacol Sci","authors":["Li, C","Xu, B-H"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32373998","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.26355/eurrev_202004_21044","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496310444036,"score":9.490897,"similar":[{"pmid":32368792,"title":"Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2.","text":["Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2.","As of April 9, 2020, a novel coronavirus (SARS-CoV-2) had caused 89,931 deaths and 1,503,900 confirmed cases worldwide, which indicates an increasingly severe and uncontrollable situation. Initially, little was known about the virus. As research continues, we have learned the genome structure, epidemiological and clinical characteristics and pathogenic mechanisms of SARS-CoV-2. Based on these discoveries, identifying potential targets involved in the processes of virus pathogenesis is urgently needed, and discovering or developing promising drugs based on potential targets is the most pressing need. Therefore, we summarize the potential therapeutic targets involved in virus pathogenesis and discuss the advancements, possibilities and significance of promising drugs based on these targets for treating SARS-CoV-2. This review will facilitate the identification of potential targets and provide promising clues for drug development that can be translated into clinical applications for combating SARS-CoV-2.","Br J Pharmacol","Zhou, Hong","Fang, Yan","Xu, Tao","Ni, Wei-Jian","Shen, Ai-Zong","Meng, Xiao-Ming","32368792"],"abstract":["As of April 9, 2020, a novel coronavirus (SARS-CoV-2) had caused 89,931 deaths and 1,503,900 confirmed cases worldwide, which indicates an increasingly severe and uncontrollable situation. Initially, little was known about the virus. As research continues, we have learned the genome structure, epidemiological and clinical characteristics and pathogenic mechanisms of SARS-CoV-2. Based on these discoveries, identifying potential targets involved in the processes of virus pathogenesis is urgently needed, and discovering or developing promising drugs based on potential targets is the most pressing need. Therefore, we summarize the potential therapeutic targets involved in virus pathogenesis and discuss the advancements, possibilities and significance of promising drugs based on these targets for treating SARS-CoV-2. This review will facilitate the identification of potential targets and provide promising clues for drug development that can be translated into clinical applications for combating SARS-CoV-2."],"journal":"Br J Pharmacol","authors":["Zhou, Hong","Fang, Yan","Xu, Tao","Ni, Wei-Jian","Shen, Ai-Zong","Meng, Xiao-Ming"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32368792","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bph.15092","keywords":["sars-cov-2","epidemiological and clinical characteristics","outbreak","potential targets","promising drugs"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496218169344,"score":132.92085},{"pmid":32437797,"title":"The current understanding and potential therapeutic options to combat COVID-19.","text":["The current understanding and potential therapeutic options to combat COVID-19.","The ongoing wreaking global outbreak of the novel human beta coronavirus (CoV) pathogen was presumed to be from a seafood wholesale market in Wuhan, China, belongs to the Coronaviridae family in the Nidovirales order. The virus is highly contagious with potential human-human transmission which was named as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has spread across six continents and emerged as a global pandemic in short span with alarming levels of spread and severity. This virus associated symptoms and infectious respiratory illness is designated as coronavirus disease 19 (COVID-19). The SARS-CoV-2 possesses enveloped club-like spike protein projections with positive-sense large RNA genome and has a unique replication strategy. This virus was believed to have zoonotic origin with genetical identity to bat and pangolin CoV. In the current review, we introduce a general overview about the human CoVs and the associated diseases, the origin, structure, replication and key clinical events that occur in the COVID-19 pathogenicity. Furthermore, we focused on possible therapeutic options such as repurposing drugs including antimalarials, antivirals, antiparasitic drugs, and anti-HIV drugs, as well as monoclonal antibodies, vaccines as potential treatment options. Also we have summarized the latest research progress on the usage of stem cell therapy, human convalescent serum, interferon's, in the treatment of COVID-19.","Life Sci","Pooladanda, Venkatesh","Thatikonda, Sowjanya","Godugu, Chandraiah","32437797"],"abstract":["The ongoing wreaking global outbreak of the novel human beta coronavirus (CoV) pathogen was presumed to be from a seafood wholesale market in Wuhan, China, belongs to the Coronaviridae family in the Nidovirales order. The virus is highly contagious with potential human-human transmission which was named as the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has spread across six continents and emerged as a global pandemic in short span with alarming levels of spread and severity. This virus associated symptoms and infectious respiratory illness is designated as coronavirus disease 19 (COVID-19). The SARS-CoV-2 possesses enveloped club-like spike protein projections with positive-sense large RNA genome and has a unique replication strategy. This virus was believed to have zoonotic origin with genetical identity to bat and pangolin CoV. In the current review, we introduce a general overview about the human CoVs and the associated diseases, the origin, structure, replication and key clinical events that occur in the COVID-19 pathogenicity. Furthermore, we focused on possible therapeutic options such as repurposing drugs including antimalarials, antivirals, antiparasitic drugs, and anti-HIV drugs, as well as monoclonal antibodies, vaccines as potential treatment options. Also we have summarized the latest research progress on the usage of stem cell therapy, human convalescent serum, interferon's, in the treatment of COVID-19."],"journal":"Life Sci","authors":["Pooladanda, Venkatesh","Thatikonda, Sowjanya","Godugu, Chandraiah"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437797","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.lfs.2020.117765","keywords":["covid-19","repurposing drugs","sars-cov-2","spike proteins","zoonotic origin"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667521393750704129,"score":132.44138},{"pmid":32434211,"title":"Viral and host factors related to the clinical outcome of COVID-19.","text":["Viral and host factors related to the clinical outcome of COVID-19.","In December 2019, the Coronavirus disease 2019 (COVID-19), caused by a novel coronavirus SARS-CoV-2, emerged in Wuhan, Hubei province, China(1) and soon spread across the world. In this ongoing pandemic, public health concerns and the urgent need for effective therapeutic measures require a deep understanding of its epidemiology, transmissibility and pathogenesis. Here we analyzed the clinical, molecular and immunological data from 326 confirmed cases of COVID-19 in Shanghai. Genomic sequences of SARS-CoV-2 assembled from 112 quality samples together with sequences in the Global Initiative on Sharing All Influenza Data (GISAID) showed a stable evolution and suggested two major lineages with differential exposure history during the early phase of the outbreak in Wuhan. Nevertheless, they exhibited similar virulence and clinical outcomes. Lymphocytopenia, especially the reduced CD4(+) and CD8(+) T cell counts upon admission, was predictive of disease progression. High levels of IL-6 and IL-8 during treatment were observed in patients with severe or critical disease and correlated with decreased lymphocyte count. The determinants of disease severity seemed to stem mostly from host factors such as age, lymphocytopenia, and its associated cytokine storm, whereas viral genetic variation did not significantly affect the outcomes.","Nature","Zhang, Xiaonan","Tan, Yun","Ling, Yun","Lu, Gang","Liu, Feng","Yi, Zhigang","Jia, Xiaofang","Wu, Min","Shi, Bisheng","Xu, Shuibao","Chen, Jun","Wang, Wei","Chen, Bing","Jiang, Lu","Yu, Shuting","Lu, Jing","Wang, Jinzeng","Xu, Mingzhu","Yuan, Zhenghong","Zhang, Qin","Zhang, Xinxin","Zhao, Guoping","Wang, Shengyue","Chen, Saijuan","Lu, Hongzhou","32434211"],"abstract":["In December 2019, the Coronavirus disease 2019 (COVID-19), caused by a novel coronavirus SARS-CoV-2, emerged in Wuhan, Hubei province, China(1) and soon spread across the world. In this ongoing pandemic, public health concerns and the urgent need for effective therapeutic measures require a deep understanding of its epidemiology, transmissibility and pathogenesis. Here we analyzed the clinical, molecular and immunological data from 326 confirmed cases of COVID-19 in Shanghai. Genomic sequences of SARS-CoV-2 assembled from 112 quality samples together with sequences in the Global Initiative on Sharing All Influenza Data (GISAID) showed a stable evolution and suggested two major lineages with differential exposure history during the early phase of the outbreak in Wuhan. Nevertheless, they exhibited similar virulence and clinical outcomes. Lymphocytopenia, especially the reduced CD4(+) and CD8(+) T cell counts upon admission, was predictive of disease progression. High levels of IL-6 and IL-8 during treatment were observed in patients with severe or critical disease and correlated with decreased lymphocyte count. The determinants of disease severity seemed to stem mostly from host factors such as age, lymphocytopenia, and its associated cytokine storm, whereas viral genetic variation did not significantly affect the outcomes."],"journal":"Nature","authors":["Zhang, Xiaonan","Tan, Yun","Ling, Yun","Lu, Gang","Liu, Feng","Yi, Zhigang","Jia, Xiaofang","Wu, Min","Shi, Bisheng","Xu, Shuibao","Chen, Jun","Wang, Wei","Chen, Bing","Jiang, Lu","Yu, Shuting","Lu, Jing","Wang, Jinzeng","Xu, Mingzhu","Yuan, Zhenghong","Zhang, Qin","Zhang, Xinxin","Zhao, Guoping","Wang, Shengyue","Chen, Saijuan","Lu, Hongzhou"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32434211","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1038/s41586-020-2355-0","locations":["Wuhan","Hubei","Shanghai","Wuhan","Lymphocytopenia","lymphocytopenia"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1667342288242606081,"score":127.08849},{"pmid":32284951,"pmcid":"PMC7144823","title":"Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.","text":["Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time of this review, COVID-19 has been diagnosed in more than 200 000 patients and associated with over 8000 deaths (Centers for Disease Control and Prevention, World Health Organization). On behalf of the Society of Infectious Diseases Pharmacists, we herein summarize the current evidence as of March 18, 2020 to provide guidance on potential COVID-19 treatment options. It is important to caution readers that new data emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the subsequent agents is still under investigation. Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness. We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion.","Open Forum Infect Dis","McCreary, Erin K","Pogue, Jason M","32284951"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time of this review, COVID-19 has been diagnosed in more than 200 000 patients and associated with over 8000 deaths (Centers for Disease Control and Prevention, World Health Organization). On behalf of the Society of Infectious Diseases Pharmacists, we herein summarize the current evidence as of March 18, 2020 to provide guidance on potential COVID-19 treatment options. It is important to caution readers that new data emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the subsequent agents is still under investigation. Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness. We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion."],"journal":"Open Forum Infect Dis","authors":["McCreary, Erin K","Pogue, Jason M"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32284951","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1093/ofid/ofaa105","keywords":["covid-19","sars-cov-2","hydroxychloroquine","lopinavir/ritonavir","remdesivir"],"topics":["Prevention"],"weight":1,"_version_":1666138491303493633,"score":124.77565},{"pmid":32442720,"title":"A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).","text":["A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).","The epidemic of pneumonia (COVID-19) caused by novel coronavirus (SARS-CoV-2) infection has been listed as a public health emergency of international concern by the World Health Organization (WHO), and its harm degree is defined as a global \"pandemic\". At present, the efforts of various countries focus on the rapid diagnosis and isolation of patients, as well as to find a treatment that can combat the most serious impact of the disease. The number of reported COVID-19 virus infections is still increasing. Unfortunately, no drugs or vaccines have been approved for the treatment of human coronaviruses, but there is an urgent need for in-depth research on emerging human infectious coronaviruses. Clarification transmission routes and pathogenic mechanisms, and identification of potential drug treatment targets will promote the development of effective prevention and treatment measures. In the absence of confirmed effective treatments, due to public health emergencies, it is essential to study the possible effects of existing approved antivirals drugs or Chinese herbal medicines for SARS-CoV-2. This review summarizes the epidemiological characteristics, pathogenesis, virus structure and targeting strategies of COVID-19. Meanwhile, this review also focus on the re-purposing of clinically approved drugs and Chinese herbal medicines that may be used to treat COVID-19 and provide new ideas for the discovery of small molecular compounds with potential therapeutic effects on novel COVID-19.","Pharmacol Res","Huang, Fangfang","Li, Ying","Leung, Elaine Lai-Han","Liu, Xiaohua","Liu, Kaifeng","Wang, Qu","Lan, Yongqi","Li, Xiaoling","Yu, Haibing","Cu, Liao","Luo, Hui","Luo, Lianxiang","32442720"],"abstract":["The epidemic of pneumonia (COVID-19) caused by novel coronavirus (SARS-CoV-2) infection has been listed as a public health emergency of international concern by the World Health Organization (WHO), and its harm degree is defined as a global \"pandemic\". At present, the efforts of various countries focus on the rapid diagnosis and isolation of patients, as well as to find a treatment that can combat the most serious impact of the disease. The number of reported COVID-19 virus infections is still increasing. Unfortunately, no drugs or vaccines have been approved for the treatment of human coronaviruses, but there is an urgent need for in-depth research on emerging human infectious coronaviruses. Clarification transmission routes and pathogenic mechanisms, and identification of potential drug treatment targets will promote the development of effective prevention and treatment measures. In the absence of confirmed effective treatments, due to public health emergencies, it is essential to study the possible effects of existing approved antivirals drugs or Chinese herbal medicines for SARS-CoV-2. This review summarizes the epidemiological characteristics, pathogenesis, virus structure and targeting strategies of COVID-19. Meanwhile, this review also focus on the re-purposing of clinically approved drugs and Chinese herbal medicines that may be used to treat COVID-19 and provide new ideas for the discovery of small molecular compounds with potential therapeutic effects on novel COVID-19."],"journal":"Pharmacol Res","authors":["Huang, Fangfang","Li, Ying","Leung, Elaine Lai-Han","Liu, Xiaohua","Liu, Kaifeng","Wang, Qu","Lan, Yongqi","Li, Xiaoling","Yu, Haibing","Cu, Liao","Luo, Hui","Luo, Lianxiang"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32442720","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.phrs.2020.104929","keywords":["covid-19","chinese herbal medicines","pneumonia","sars-cov-2","therapeutic agents","treatment"],"locations":["Chinese","Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667535119519318016,"score":122.97859}]}